Acta Poloniae Pharmaceutica (Jun 2023)

The application of cannabidiol in the treatment of glioblastoma

  • Anna Rybarczyk,
  • Aleksandra Majchrzak-Celińska,
  • Violetta Krajka-Kuźniak

DOI
https://doi.org/10.32383/appdr/163414
Journal volume & issue
Vol. 80, no. 2
pp. 207 – 217

Abstract

Read online

Glioblastoma multiforme (GBM), a high-grade astrocytoma, is an incurable brain tumor associated with genetic heterogeneity and dysregulated signaling pathways. As alternations of the endocannabinoid system have been demonstrated in GBM cells, the substances affecting its key elements may potentially inhibit tumor progression. Preclinical models indicate that CBD inhibits GBM tumor growth by inhibiting cellular proliferation, migration, and invasion but also promotes autophagy and apoptosis of tumor cells. Moreover, clinical trials indicate the safety and positive results regarding the survival of GBM patients upon cannabinoids treatment. Nevertheless, more human clinical trials with large sample sizes are urgently needed to implement cannabinoids, including CBD, into standard GBM treatment.

Keywords